Press Releases

See All »

Media Coverage

December 8, 2014

New to the Street Interview with NeoStem

Chairman and CEO Dr. Robin L. Smith and Chief Medical Officer Dr. Douglas Losordo join New to the Street host Ken Evseroff to discuss NeoStem's pipeline of therapeutic products, the recent release of Phase 2 PreSERVE AMI clinical trial initial results, and an upcoming Phase 3 clinical trial investigating the Company's targeted cancer immunotherapy, NBS20, in patients with late-stage metastatic melanoma.

November 17, 2014

Dr. Arshed Quyyum interviewed at American Heart Association Scientific Sessions

Dr. Arshed Quyyum, MD, FACC, Professor of Medicine at Emory University and Lead Principal Investigator of NeoStem’s PreSERVE AMI clinical study, discusses data released from trial at the American Heart Association's Scientific Sessions.

October 13, 2014

NeoStem Acquires Its Way to the Top

Dr. Robin Smith, CEO of NeoStem, discusses how the acquisition of six biotech companies has enabled her to find talent in the emerging industry of cell therapy.

See All »

Upcoming Events


April 22, 2015 - 2:00 PM ET
Jacob Javits Center, New York, New York

• Presenter: Dr. Robert Preti, Chief Scientific Officer
• Topic: Development by Design: A Strategy to Support Commercial Success

American Association for Cancer Research Annual Meeting

April 22, 2015 - 8:00 AM ET
Pennsylvania Convention Center, Philadelphia, Pennsylvania

• Presenter: Dr. Andrew N. Cornforth, Manufacturing Director
• Poster: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma

Stem Cell Summit 2015

April 28, 2015 - 4:05 PM ET
Hyatt Regency, Boston, Massachusetts

• Presenter: Dr. Hans Keirstead, President, NeoStem Oncology
• Topic: Immunotherapy – Revolution in Cancer

See All »


See All »

NeoStem - Cell Therapy Development - Media Section